NASDAQ:EVGN - Evogene Stock Price, News, & Analysis Sign in or create an account to add this stock to your watchlist. Get Started $2.09 -0.25 (-10.68 %) (As of 01/16/2019 06:00 AM ET)Previous Close$2.3368Today's Range$2.09 - $2.1052-Week Range$1.98 - $4.20Volume3,569 shsAverage Volume6,388 shsMarket Capitalization$60.18 millionP/E RatioN/ADividend YieldN/ABeta1.01 ProfileDiscussionChartEarningsFinancialsInstitutional OwnershipHeadlinesSEC FilingsSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email Evogene Ltd., a biotechnology company, focuses on the enhancement of crop productivity and performance in the United States, Germany, and internationally. It operates through three segments: Evogene, Evofuel, and Biomica. The Evogene segment develops seed traits, ag-chemical products, and ag-biological products to enhance plant performance. This segment develops seed traits enhancing plant yield and tolerance to abiotic stresses, such as enhanced tolerance to drought, heat, and salinity, as well as seed traits for enhancing plant resistance to biotic stresses, including resistance to diseases, pests, and insects; novel herbicides; and bio-stimulants and bio-pesticides comprising microbial-based products that are applied externally to the plant for yield enhancement. Its products focus on various crops, such as corn, soybean, wheat, rice, and cotton. The Evofuel segment develops enhanced species of the castor bean plant to serve as a source of feedstock for biofuel and other industrial uses. The Biomica segment discovers and develops human microbiome-based therapeutics for the treatment of immune-mediated and infectious diseases. The company has strategic collaborations with various agricultural companies, including BASF, Bayer, DuPont, Monsanto, Dow Chemical, Syngenta, and Insolo Agroindustrial S.A. Evogene Ltd. was founded in 1999 and is headquartered in Rehovot, Israel. Receive EVGN News and Ratings via Email Sign-up to receive the latest news and ratings for EVGN and its competitors with MarketBeat's FREE daily newsletter. Industry, Sector and Symbol Stock Exchange NASDAQ Industry Agricultural chemicals Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:EVGN Previous Symbol CUSIPN/A Webwww.evogene.com Phone972-8931-1900Debt Debt-to-Equity RatioN/A Current Ratio11.86 Quick Ratio11.86Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual Sales$3.38 million Price / Sales15.92 Cash FlowN/A Price / Cash FlowN/A Book Value$2.69 per share Price / Book0.78Profitability EPS (Most Recent Fiscal Year)N/A Net Income$-20,830,000.00 Net Margins-1,147.40% Return on Equity-33.97% Return on Assets-30.11%Miscellaneous Employees205 Outstanding Shares25,750,000Market Cap$60.18 million OptionableNot Optionable Evogene (NASDAQ:EVGN) Frequently Asked Questions What is Evogene's stock symbol? Evogene trades on the NASDAQ under the ticker symbol "EVGN." How were Evogene's earnings last quarter? Evogene Ltd (NASDAQ:EVGN) announced its earnings results on Wednesday, November, 14th. The biotechnology company reported ($0.19) earnings per share for the quarter. The biotechnology company earned $0.37 million during the quarter. Evogene had a negative return on equity of 33.97% and a negative net margin of 1,147.40%. View Evogene's Earnings History. When is Evogene's next earnings date? Evogene is scheduled to release their next quarterly earnings announcement on Wednesday, February 27th 2019. View Earnings Estimates for Evogene. Has Evogene been receiving favorable news coverage? Headlines about EVGN stock have been trending negative on Wednesday, according to InfoTrie. The research group identifies positive and negative media coverage by reviewing more than six thousand blog and news sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores closest to five being the most favorable. Evogene earned a coverage optimism score of -2.5 on InfoTrie's scale. They also assigned headlines about the biotechnology company a news buzz of 2.0 out of 10, meaning that recent media coverage is very unlikely to have an effect on the stock's share price in the immediate future. Who are some of Evogene's key competitors? Some companies that are related to Evogene include Marrone Bio Innovations (MBII), China Green Agriculture (CGA), Bion Environmental Technologies (BNET), SenesTech (SNES), Arcadia Biosciences (RKDA), Kiwa Bio-Tech Products Group (KWBT), Cavitation Technologies (CVAT), Eden Research (EDEN), Monsanto (MON), Nufarm (NUF), Syngenta (SYT), Terra Nitrogen (TNH) and Wynnstay Group (WYN). Who are Evogene's key executives? Evogene's management team includes the folowing people: Mr. Ofer Haviv, CEO & Pres (Age 52)Mr. Alex Taskar, Chief Financial Officer (Age 52)Mr. Ido Dor, Exec. VP & GM of Ag-Biologicals (Age 42)Mr. Eran Kosover, Exec. VP & GM of Ag-Chemicals (Age 41)Mr. Mark Kapel, Exec. VP of Technology (Age 41) How do I buy shares of Evogene? Shares of EVGN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab. What is Evogene's stock price today? One share of EVGN stock can currently be purchased for approximately $2.09. How big of a company is Evogene? Evogene has a market capitalization of $60.18 million and generates $3.38 million in revenue each year. Evogene employs 205 workers across the globe. What is Evogene's official website? The official website for Evogene is http://www.evogene.com. How can I contact Evogene? Evogene's mailing address is 13 GAD FEINSTEIN STREET PARK REHOVOT P.O.B 2100, REHOVOT L3, 76121. The biotechnology company can be reached via phone at 972-8931-1900 or via email at [email protected] MarketBeat Community Rating for Evogene (NASDAQ EVGN)Community Ranking: 2.3 out of 5 ( )Outperform Votes: 152 (Vote Outperform)Underperform Votes: 185 (Vote Underperform)Total Votes: 337MarketBeat's community ratings are surveys of what our community members think about Evogene and other stocks. Vote "Outperform" if you believe EVGN will outperform the S&P 500 over the long term. Vote "Underperform" if you believe EVGN will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 1/16/2019 by MarketBeat.com StaffFeatured Article: What is the quiet period?